Summary of Sight Sciences Conference Call Company Overview - **Company**: Sight Sciences (NasdaqGS: SGHT) - **Industry**: Eye Care, specifically focusing on treatments for meibomian gland disease (MGD) and surgical glaucoma Key Highlights from the Third Quarter - **TearCare Market Access Wins**: Successful market access for TearCare, a treatment for evaporative dry eye disease, after a decade of efforts [2][3] - **Surgical Glaucoma Performance**: Strong performance in the surgical glaucoma business, particularly in Minimally Invasive Glaucoma Surgery (MIGS) despite industry headwinds [2][3] - **Restructuring and Leadership Changes**: Streamlined operations and promoted key personnel to enhance focus on growth opportunities [3] TearCare Product Insights - **Clinical Outcomes**: TearCare demonstrated superior clinical outcomes in a randomized controlled trial (RCT) compared to standard prescription eye drops, showing durability of treatment effects over two years [6][7] - **Economic Value Proposition**: TearCare is not only clinically effective but also cost-effective, making it an attractive option for payers [7][8] - **Stakeholder Benefits**: All stakeholders benefit from reimbursed TearCare, including patients, doctors, and payers, creating a sustainable business model with high-margin recurring revenue [8][9] Market Strategy and Growth Potential - **Established Customer Base**: Over 70,000 cash pay procedures performed, indicating high demand for TearCare [14] - **Payer Density Strategy**: Focus on increasing payer density in key markets (Texas and Florida) to enhance reimbursement opportunities [15][16] - **Sales Projections**: Anticipated modest sales of $500,000 to $1,000,000 in the fourth quarter, with significant ramp-up expected in 2026 [18] Long-Term Market Potential - **Addressable Market Size**: Approximately 19 million people suffer from dry eye disease, with 6 to 8 million having moderate to severe MGD, indicating a large market opportunity [33][34] - **Recurring Treatment Model**: Patients are expected to return for treatments every six to twelve months, enhancing the total addressable market (TAM) [34][35] MIGS and Surgical Glaucoma Insights - **Market Share Gains**: Sight Sciences has gained market share in the MIGS segment, attributed to strong execution and the comprehensive nature of the Omni device [39][40] - **Growth in Combo Cataract Market**: The company aims to expand its presence in the combo cataract MIGS market, which is currently less than 50% penetrated [45] Financial Health and Guidance - **Balance Sheet Strength**: Over $90 million in cash, with a pathway to break-even without additional equity capital [52] - **Operational Expenditure**: Adjusted operational expenditure of $20 million in Q3, with guidance for Q4 suggesting a similar range for 2026 [53] Conclusion - **Future Outlook**: The company is positioned for growth in both the TearCare and surgical glaucoma segments, with a focus on executing its market strategies effectively and maintaining financial discipline as it scales operations [54][53]

Summary of Glaukos Conference Call Company Overview - **Company**: Glaukos Corporation - **Industry**: Medical Technology (MedTech), specifically focused on ophthalmology and glaucoma treatment Key Financial Highlights - **Q3 Results**: Achieved record glaucoma revenues and total revenues, reporting $40 million from iDose for the quarter, a sequential increase from Q2 [7][40] - **Guidance Update**: Raised annual revenue guidance from $490 million to $495 million, indicating strong business growth as the year closes [7][40] Product Insights iDose - **Market Potential**: iDose is positioned to expand the total addressable market (TAM) for glaucoma treatments, with an estimated 22 million eyes affected by ocular hypertension and glaucoma, of which 12 million are currently treated [44][45] - **Clinical Evidence**: iDose has undergone two phase 3 trials with over 1,150 patients, demonstrating efficacy and safety [20][21] - **Future Growth**: Expected to exit 2025 with a run rate of approximately $180 million, with projections for 2026 around $220 million [42][40] EPIAXA - **New Approval**: EPIAXA is a new treatment for keratoconus that does not require corneal debridement, improving patient experience [115][121] - **Market Opportunity**: Currently, only 10,000 patients are treated annually, but there is potential for 50,000 patients who are not receiving treatment [117][119] - **Investment Focus**: Significant investments will be made to educate and identify patients, with a focus on establishing market access and reimbursement [123][129] Market Dynamics - **Interventional Glaucoma (IG)**: The company is focused on promoting interventional glaucoma treatments, which aim to address noncompliance with topical medications [49][78] - **Surgeon Adoption**: The adoption of IG practices is still in early stages, with a need for education and support for surgeons to implement these treatments effectively [186][190] Regulatory and Reimbursement Landscape - **MACs and J Code**: All seven Medicare Administrative Contractors (MACs) are now paying for the J code, with ongoing efforts to establish pro fees for remaining MACs [93][100] - **Future Reimbursement**: The establishment of a J code is expected to enhance commercial plan adoption and streamline reimbursement processes [135][139] R&D and Innovation - **Pipeline Development**: Glaukos has 14 publicly disclosed pipeline programs, including next-generation iDose and iLution for blepharitis [167][169] - **Focus on Innovation**: The company aims to build a world-class ophthalmology company through continuous innovation and product development [166][167] International Market Outlook - **Growth Drivers**: The approval of iStent infinite in Europe is expected to drive growth, with strong demand observed at recent conferences [193][195] - **Market Access Challenges**: Each international market presents unique challenges, but there is significant room for growth in unlocking potential [203][205] Conclusion - **Strategic Focus**: Glaukos is committed to addressing unmet patient needs through innovative products and expanding market access, with a clear path towards profitability and growth in the interventional glaucoma market [209][210]

Core Insights - Brown Capital Management sold 376,359 shares of Glaukos Corporation for an estimated $34.6 million in Q3, reducing its holding to 762,760 shares valued at $62.2 million [2][3] - The sale decreased Glaukos Corporation's weight in Brown Capital Management's portfolio to 2.6% of 13F assets [3][6] - Glaukos shares have declined approximately 34% over the past year, significantly underperforming the S&P 500, which is up nearly 15% [3] Company Overview - Glaukos Corporation specializes in ophthalmic medical technology, focusing on innovative micro-scale devices and pharmaceutical solutions for glaucoma and related eye disorders [5] - The company reported a total revenue of $433 million and a net income loss of $92.8 million for the trailing twelve months (TTM) [4] - As of the latest market close, Glaukos's stock price was $84.35, with a market capitalization of $4.8 billion [4] Recent Performance - The company's revenue grew by 28% year-over-year to $105.5 million, but it faced larger-than-expected losses and rising expenses, leading to a decline in stock price [7] - Management anticipates sales between $475 million and $485 million for 2025, while acknowledging challenges related to currency exchange and market entry [8] Strategic Positioning - Glaukos aims to expand its product portfolio and leverage proprietary technology platforms to meet unmet clinical needs in ophthalmology [5] - The company's competitive advantage lies in its focus on minimally invasive therapies and a robust pipeline targeting multiple ophthalmic indications [5][8]

Financial Performance - Net sales for the three months ended September 30, 2025, were $133.5 million, a 38.1% increase from $96.7 million in the same period of 2024[123] - Gross margin for the three months ended September 30, 2025, was 78%, compared to 77% for the same period in 2024[123] - The company incurred net losses of $16.2 million and $54.0 million for the three and nine months ended September 30, 2025, respectively, compared to net losses of $21.4 million and $112.8 million for the same periods in 2024[123] - Net sales for the nine months ended September 30, 2025, were $364.3 million, a 31% increase from $278.0 million in the same period of 2024[182] - U.S. net sales of glaucoma products increased by 48% to $212.2 million, driven by higher volumes of iDose TR[183] - International sales of glaucoma products rose by 18% to $89.7 million, with significant growth in key markets like France, Japan, and the UK[184] - Gross profit for the nine months ended September 30, 2025, was $284.3 million, reflecting a gross margin of 78%, up from 76% in 2024[186] Expenses - SG&A expenses increased by 30% to $83.0 million for the three months ended September 30, 2025, up from $64.0 million in 2024[173] - R&D expenses rose by 10% to $38.1 million for the three months ended September 30, 2025, compared to $34.7 million in 2024[177] - Selling, general and administrative (SG&A) expenses increased by 23% to $237.0 million, with $17.1 million attributed to increased compensation and related employee costs[189] - Research and development (R&D) expenses totaled $107.0 million, with $75.6 million in core R&D and $31.4 million in clinical expenses[191] Cash Flow and Investments - Cash and cash equivalents as of September 30, 2025, totaled approximately $98.2 million, with short-term investments at $175.5 million[198] - Operating activities used $21.6 million in net cash for the nine months ended September 30, 2025, a significant improvement from $61.8 million used in the same period of 2024[207] - The company plans to invest over $80.0 million in a new 200,000 square foot R&D and manufacturing facility in Huntsville, Alabama, with construction expected to begin in 2026[204] - For the nine months ended September 30, 2025, the company received $18.2 million from stock options and employee stock purchases[216] - For the nine months ended September 30, 2024, the company received $36.9 million from stock options and employee stock purchases[217] Market Developments - The company received FDA approval for Epioxa on October 20, 2025, which is the first incision-free topical drug therapy for keratoconus, with plans to commercialize in Q1 2026[125] - The approval of Epioxa is anticipated to disrupt the U.S. Corneal Health franchise as the market transitions from Photrexa to Epioxa[145] - The establishment of reimbursement for the iDose TR procedure is expected to increase utilization as it becomes more consistent across all MACs[142] - The international glaucoma business saw a positive impact of approximately 330 basis points on net sales growth for the three months ended September 30, 2025, primarily due to currency fluctuations[133] Challenges - The company experienced higher costs for certain components and raw materials due to ongoing supply chain challenges and inflationary pressures[129] - Non-operating income decreased to $0.4 million for the three months ended September 30, 2025, from $3.4 million in 2024, primarily due to changes in unrealized foreign currency amounts[179] - There have been no significant changes to material cash requirements as of September 30, 2025, compared to the previous disclosures[219] - There have been no material changes in exposure to market risk since December 31, 2024[225]

Core Insights - Glaukos Corporation reported a narrower adjusted loss of 16 cents per share for Q3 2025, better than the Zacks Consensus Estimate of a 27-cent loss and improved from a 28-cent loss in the same quarter last year [1] - The company achieved revenues of $133.5 million, reflecting a 38% year-over-year increase and surpassing the Zacks Consensus Estimate by 9.5% [2] Revenue Details - Net sales for Glaucoma reached $110.2 million, up 45% year over year, while Corneal Health sales totaled $23.3 million [3] Margin Analysis - Gross profit increased by 41.3% year over year to $104.7 million, with an adjusted gross margin of 84%, up from 82% in the previous year [4] - Selling, general, and administrative expenses rose by 30% year over year to $83 million, while research and development expenses increased by 10% to $38.1 million [4] Operating Performance - The operating loss decreased to $16.4 million from $24.7 million in the prior year, with an adjusted operating loss of $9.3 million, an improvement from the $18.4 million loss in the same quarter last year [5] Financial Update - At the end of Q3 2025, Glaukos had cash and cash equivalents and short-term investments totaling $277.5 million, slightly down from $278.6 million at the end of Q2 2025 [6] 2025 Guidance - The company raised its 2025 revenue guidance to a range of $490-$495 million, up from the previous estimate of $480-$486 million, with a loss per share estimate of 90 cents, indicating a 51.6% year-over-year improvement [7] Strategic Developments - The FDA approval of Epioxa represents a significant advancement, introducing a next-generation, incision-free therapy for keratoconus, enhancing Glaukos' rare disease portfolio [10] - The company is focused on disciplined capital allocation, robust R&D investment, and the upcoming Huntsville facility to support innovation and manufacturing scale, positioning itself for sustainable growth [11]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Financial Data and Key Metrics Changes - Glaukos Corporation reported record third quarter consolidated net sales of $133.5 million, up 38% on a reported basis or 37% on a constant currency basis compared to the same quarter last year [7] - The company raised its full year 2025 net sales guidance range to $490 million-$495 million from the previous range of $480 million-$486 million [7][26] Business Line Data and Key Metrics Changes - The U.S. glaucoma franchise achieved record third quarter net sales of $80.8 million, reflecting a strong year-over-year growth of 57%, driven by iDose TR, which generated approximately $40 million in sales [8] - The international glaucoma franchise delivered net sales of $29.4 million, representing a year-over-year growth of 20% on a reported basis and 17% on a constant currency basis [9] - The corneal health franchise reported net sales of $23.3 million, with Photrexa net sales contributing $20.3 million, reflecting a year-over-year growth of 13% [10] Market Data and Key Metrics Changes - Surgeons showed high initial interest in iStent infinite during its commercial launch activities in key European markets, indicating strong potential for growth in the international market [9] - The company continues to scale its international infrastructure to drive growth as a standard of care in major markets worldwide [9] Company Strategy and Development Direction - Glaukos is focused on advancing its strategic priorities, evolving into a diversified ophthalmic leader with growth drivers across multiple geographies and disease states [11] - The FDA approval of Epioxa marks a significant milestone, introducing a new standard of care for keratoconus patients and practitioners [12] - The company plans to increase investments in patient awareness and access to address the challenges of underdiagnosis and under-treatment in keratoconus [18][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of Epioxa to deliver exceptional value to patients and the healthcare system, emphasizing the importance of education and awareness in driving patient access [22] - The company anticipates Epioxa will be commercially available in the first quarter of 2026, with a focus on establishing a site of care network and addressing payer adoption challenges [24] - A preliminary revenue guidance range of $600 million-$620 million for 2026 was introduced, reflecting expectations for continued growth from iDose TR and the launch of Epioxa [26][27] Other Important Information - Glaukos has invested over $1 billion in R&D to develop a robust pipeline focused on chronic and rare ophthalmic diseases [21] - The company is transitioning from Photrexa to Epioxa, with plans to discontinue Photrexa's commercial availability in 2026 while ensuring continuity of care for existing patients [25] Q&A Session Summary Question: Discussion on iDose and CAC meeting - Management discussed the rationale behind the CAC meeting, emphasizing the need to educate MACs on the unmet need that iDose addresses and the robust data supporting its utilization [30][31] Question: Confidence in Epioxa pricing and 2026 outlook - Management expressed confidence in executing the pricing strategy for Epioxa, highlighting the importance of educating payers on the therapy's benefits and the cost implications of untreated keratoconus [36][37] Question: iDose performance and future growth - Management provided insights into iDose's performance, noting broad-based growth and the importance of establishing reimbursement structures to support future adoption [44][46] Question: Epioxa's market development and education efforts - Management outlined targeted awareness and education campaigns to identify and reach keratoconus patients earlier in their disease journey, emphasizing the need for a comprehensive approach [77]

Financial Data and Key Metrics Changes - Glaukos Corporation reported record third quarter consolidated net sales of $133.5 million, up 38% on a reported basis or 37% on a constant currency basis compared to the same quarter last year [7] - The company raised its full year 2025 net sales guidance range to $490 to $495 million from a previous range of $480 to $486 million [7][24] Business Line Data and Key Metrics Changes - The U.S. glaucoma franchise achieved record third quarter net sales of $80.8 million, reflecting a strong year-over-year growth of 57%, driven by iDose TR, which generated approximately $40 million in sales [8] - The international glaucoma franchise delivered net sales of $29.4 million, representing a year-over-year growth of 20% on a reported basis and 17% on a constant currency basis [9] - The corneal health franchise reported net sales of $23.3 million, with Votrexa contributing $20.3 million, reflecting a year-over-year growth of 13% [10] Market Data and Key Metrics Changes - Surgeons showed high initial interest in iStent Infinite during its commercial launch activities in key European markets, indicating strong potential for growth in the international market [9] - The company continues to scale its international infrastructure to drive growth as a standard of care in various regions [9] Company Strategy and Development Direction - Glaukos aims to evolve into a diversified ophthalmic leader with transformational growth drivers across multiple geographies and disease states, focusing on glaucoma and rare diseases [11] - The FDA approval of Epioxa marks a significant milestone, introducing a new standard of care for keratoconus patients with a unique incision-free treatment [12][17] - The company plans to increase investments in patient awareness and access to address the challenges of underdiagnosis and under-treatment in keratoconus [17][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of Epioxa to deliver exceptional value to patients and the healthcare system, emphasizing the importance of education and awareness in driving patient access [20][21] - The company anticipates Epioxa will be commercially available in the first quarter of 2026, with a focus on establishing a site of care network and addressing payer adoption challenges [22][24] Other Important Information - Glaukos has invested over $1 billion in R&D to develop a robust pipeline focused on chronic and rare ophthalmic diseases [19] - The company is constructing a new 200,000-square-foot research, development, and manufacturing facility in Huntsville, Alabama, to support long-term growth and innovation [19] Q&A Session Summary Question: Can you discuss the rationale behind the CAC meeting and potential outcomes? - Management highlighted the importance of educating MACs on the unmet need that iDose addresses and the robust FDA data supporting its utilization [30][31] Question: What is the confidence level regarding payer coverage for Epioxa? - Management indicated that education at the payer level is crucial, and they are optimistic about engaging in conversations to establish coverage [36] Question: Can you provide more granularity on the 2026 revenue guidance? - Management stated that the preliminary guidance reflects expectations for Epioxa's rollout and the transition from Votrexa, with more detailed insights to be provided in future calls [41][42] Question: How is iDose performing in terms of utilization? - Management reported strong sales growth for iDose, with contributions from various MAC regions and a growing trend in combination with cataract surgeries [45][46] Question: What are the expectations for patient access to Epioxa? - Management acknowledged that while there may be initial headwinds, they aim to significantly expand patient access over time through education and awareness initiatives [55]

Financial Data and Key Metrics Changes - Glaukos Corporation reported record third quarter consolidated net sales of $133.5 million, up 38% on a reported basis or 37% on a constant currency basis compared to the same quarter last year [6][7] - The company raised its full year 2025 net sales guidance range to $490 to $495 million from a previous range of $480 to $486 million [6][26] Business Line Data and Key Metrics Changes - The U.S. glaucoma franchise achieved record third quarter net sales of $80.8 million, reflecting a year-over-year growth of 57%, driven by contributions from iDose TR, which generated approximately $40 million in sales [7][8] - The international glaucoma franchise delivered net sales of $29.4 million, representing a year-over-year growth of 20% on a reported basis and 17% on a constant currency basis [9] - The corneal health franchise reported net sales of $23.3 million, with Votrexa contributing $20.3 million, reflecting a year-over-year growth of 13% [10][11] Market Data and Key Metrics Changes - The company noted strong growth in both U.S. and international markets, with the U.S. glaucoma franchise being a significant contributor to overall sales growth [7][9] - Surgeons showed high initial interest in iStent Infinite during its commercial launch activities in Europe, indicating a positive market reception [9] Company Strategy and Development Direction - Glaukos is focused on advancing its strategic priorities, evolving into a diversified ophthalmic leader with growth drivers across multiple geographies and disease states [11][26] - The company plans to increase investments in patient awareness and access for Epioxa, aiming to address the challenges of underdiagnosis and under-treatment in keratoconus [18][19] - A new 200,000-square-foot research, development, and manufacturing facility is being established in Huntsville, Alabama, to support long-term growth and innovation [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of Epioxa to transform keratoconus treatment and emphasized the importance of education and awareness in expanding patient access [21][56] - The company anticipates a slow and methodical rollout for Epioxa in 2026, with initial patient access being gated by site of care network deployment and payer adoption [24][40] - Preliminary revenue guidance for 2026 is set at $600 million to $620 million, reflecting expectations for continued growth from iDose TR and the launch of Epioxa [26][27] Other Important Information - The FDA approval of Epioxa marks a significant milestone, being the first and only FDA-approved topical drug therapy for keratoconus that does not require removal of the corneal epithelium [12][13] - The company has invested over $1 billion in R&D to develop a robust pipeline focused on chronic and rare ophthalmic diseases [20] Q&A Session Summary Question: Can you discuss the rationale of the CAC meeting and potential outcomes? - Management highlighted the importance of educating MACs on the unmet need that iDose addresses and the robust data supporting its utilization [32][34] Question: What are your views on payer coverage and reimbursement for Epioxa? - Management indicated that gaining access for Epioxa will involve educating payers about the benefits and costs associated with keratoconus progression [38][56] Question: Can you provide more granularity on the 2026 revenue guidance? - Management stated that the preliminary guidance reflects expectations from various franchises and will provide more detailed views in the fourth quarter call [44][45] Question: How is iDose performing and what is the mix of standalone versus combination procedures? - Management reported strong sales growth for iDose, with a mix of utilization in both standalone and combination procedures, though specific tracking is not available [47][50] Question: What investments are being made for Epioxa's market development? - Management emphasized targeted awareness and education efforts, particularly within the optometric community, to drive early diagnosis and treatment [81]

Financial Performance - Glaukos reported record third quarter net revenues of $133.5 million, up 38% reported and 37% on a constant currency basis compared to Q3 2024[5] - Third quarter 2025 non-GAAP revenue was $83.2 million, a 32% increase year-over-year from $63.3 million in Q3 2024[24] - Net sales for Q3 2025 reached $133.5 million, a 38.1% increase from $96.7 million in Q3 2024[36] - Total net sales for Q3 2025 reached $133.537 million, a 38.1% increase year-over-year compared to $96.670 million in Q3 2024[42] - Sequentially, total net sales increased by 7.6% from $124.120 million in Q2 2025[42] - Operational growth for total net sales was 37.3% year-over-year, excluding the effect of translational currency[42] - The currency impact on total net sales was minimal, contributing only 0.8% to the year-over-year growth[42] Revenue Breakdown - U.S. Glaucoma net revenues reached approximately $80.8 million, representing year-over-year growth of 57% driven by iDose TR sales of approximately $40 million[9] - International Glaucoma net revenues were approximately $29.4 million, reflecting a year-over-year growth of 20% reported and 17% on a constant currency basis[11] - Corneal Health net revenues were approximately $23.3 million, with U.S. Photrexa® net sales of $20.3 million, representing a 13% year-over-year growth[13] - Glaucoma product sales amounted to $29.443 million in Q3 2025, reflecting a 20.3% year-over-year growth from $24.467 million in Q3 2024[42] - Glaucoma product sales experienced a quarter-over-quarter decline of 5.8% from $31.251 million in Q2 2025[42] Guidance and Future Outlook - Full-year 2025 global consolidated net sales guidance raised to $490 - $495 million, up from previous guidance of $480 - $486 million[18] - Preliminary FY 2026 global consolidated revenue guidance expected to be $600 - $620 million[4] - Future outlook remains positive with expectations of continued growth driven by new product developments and market expansion strategies[42] Research and Development - Glaukos has invested over $800 million into R&D programs since 2018, supporting its pipeline of novel platforms[22] - The company has made significant investments in R&D, reflected in a 10% year-over-year increase in R&D expenses to $38.1 million in Q3 2025[24] - iDose TR is designed to continuously deliver glaucoma drug therapy for up to three years, with positive clinical outcomes reported[10] - Epioxa, a new treatment for keratoconus, received FDA approval and is expected to be commercially available in Q1 2026[22] - The iStent infinite product is currently undergoing an active PMA study and EU MDR certification expected in 2025[23] - iStent infinite received EU MDR certification, with commercial launch activities commencing in key European markets[22] Operating Expenses and Losses - Operating expenses for Q3 2025 were $277.5 million, a slight decrease of $1.1 million from $278.6 million in Q2 2025[24] - Operating expenses increased to $121.1 million in Q3 2025, compared to $98.7 million in Q3 2024, primarily driven by higher selling, general, and administrative expenses[36] - The company reported a net loss of $9.2 million in Q3 2025, improved from a net loss of $15.2 million in Q3 2024[24] - The net loss for Q3 2025 was $16.2 million, an improvement from a net loss of $21.4 million in Q3 2024[36] - Year-to-date net loss for 2025 was $54.0 million, improving from a net loss of $112.8 million for the same period in 2024[41] - Basic and diluted net loss per share for Q3 2025 was $0.28, compared to $0.39 in Q3 2024[36] Assets and Liabilities - Total assets as of September 30, 2025, were $999.4 million, an increase from $974.8 million at the end of 2024[37] - Cash and cash equivalents decreased to $98.2 million from $169.6 million at the end of 2024[37] - Total liabilities increased to $229.8 million as of September 30, 2025, compared to $207.8 million at the end of 2024[37] Operational Efficiency and Market Presence - The company continues to focus on expanding its international market presence, particularly in the glaucoma segment[42] - The company is committed to enhancing its operational efficiency to mitigate currency fluctuations' impact on sales[42] - The company is actively monitoring geopolitical and macroeconomic uncertainties that may impact operations[28] - The company expects minimal direct exposure to recent tariff-related policies due to its primary U.S. manufacturing and sourcing[28] Capital Expenditures and Facilities - Capital expenditures in Q3 2025 were $1.6 million, up from $1.4 million in Q3 2024[24] - The company celebrated the groundbreaking of a new research, development, and manufacturing facility in Huntsville, Alabama, aimed at supporting long-term growth[28] Non-GAAP Disclosures - Non-GAAP disclosures will be provided for further clarity on financial performance in upcoming reports[42]